发明授权
US08268566B2 Enhanced FC receptor-mediated tumor necrosis factor superfamily MRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis
有权
类风湿关节炎患者外周血白细胞增强FC受体介导的肿瘤坏死因子超家族MRNA表达
- 专利标题： Enhanced FC receptor-mediated tumor necrosis factor superfamily MRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis
- 专利标题（中）： 类风湿关节炎患者外周血白细胞增强FC受体介导的肿瘤坏死因子超家族MRNA表达
-
申请号： US12743220申请日： 2008-11-11
-
公开(公告)号： US08268566B2公开(公告)日： 2012-09-18
- 发明人: Masato Mitsuhashi , Katsuya Endo , Kazuhiko Obara , Hiroshi Izutsu , Shuji Ohta
- 申请人： Masato Mitsuhashi , Katsuya Endo , Kazuhiko Obara , Hiroshi Izutsu , Shuji Ohta
- 申请人地址： US CA Irvine JP Shinjuku-ku, Tokyo
- 专利权人： Hitachi Chemical Research Center, Inc.,Hitachi Chemical Co., Ltd.
- 当前专利权人： Hitachi Chemical Research Center, Inc.,Hitachi Chemical Co., Ltd.
- 当前专利权人地址： US CA Irvine JP Shinjuku-ku, Tokyo
- 代理机构： Knobbe Martens Olson & Bear, LLP
- 国际申请： PCT/US2008/083136 WO 20081111
- 国际公布： WO2009/070442 WO 20090604
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68 ; C12N5/078 ; A61K39/395 ; A61K38/17 ; A61P19/02 ; C07K14/425
摘要：
A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.
公开/授权文献
信息查询
